Hemostemix Inc. (CVE:HEM – Get Free Report) shares were up 71.4% on Tuesday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 592,088 shares traded hands during trading, an increase of 516% from the average daily volume of 96,162 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The firm has a market capitalization of C$10.45 million, a price-to-earnings ratio of -6.00 and a beta of 0.20. The stock’s fifty day moving average is C$0.08 and its two-hundred day moving average is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- The 3 Best Retail Stocks to Shop for in August
- 3 Stocks Helping to Bring AI to Healthcare
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- The How And Why of Investing in Oil Stocks
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
